What is the average price target for INMUNE BIO INC (INMB) stock?
10 analysts have analysed INMB and the average price target is 5.36 USD. This implies a price increase of 357.69% is expected in the next year compared to the current price of 1.17.
INMUNE BIO INC (INMB) Forecast, Price Target & Analyst Ratings
NASDAQ:INMB • US45782T1051
Current stock price
1.17 USD
-0.05 (-4.1%)
At close:
1.19 USD
+0.02 (+1.71%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for INMUNE BIO INC (INMB).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- Mar 25, 2026
- Period
- Q4 / 2025
- EPS Estimate
- -$0.27
- Revenue Estimate
Price Target Details & History
Consensus Price Target and Range
Mean target
$5.36
Upside
+ 357.69%
From current price of $1.17 to mean target of $5.36, Based on 10 analyst forecasts
Low
$2.02
Median
$5.61
High
$8.40
Price Target Revisions
1 Month
0.00%
3 Months
-37.50%
Price Target Summary
10 Wall Street analysts provided a forecast for the next 12 months for INMB. The average price target is 5.36 USD. This implies a price increase of 357.69% is expected in the next year compared to the current price of 1.17.
The average price target has been revised downward by 37.5% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
80.00%
INMB was analyzed by 10 analysts. The buy percentage consensus is at 80. So analysts seem to be have mildly positive about INMB.
In the previous month the buy percentage consensus was at a similar level.
INMB was analyzed by 10 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-11 | LUCID CAPITAL MARKETS | Upgrade | Neutral -> Buy |
| 2025-07-02 | Maxim Group | Maintains | Buy -> Buy |
| 2025-07-01 | ScotiaBank | Downgrade | Sector Outperform -> Sector Underperform |
| 2025-07-01 | BTIG | Downgrade | Buy -> Neutral |
| 2025-02-13 | Maxim Group | Maintains | Buy -> Buy |
| 2025-02-11 | ScotiaBank | Maintains | Sector Outperform -> Sector Outperform |
| 2024-10-21 | Alliance Global Partners | Initiate | Buy |
| 2024-09-27 | Raymond James | Initiate | Outperform |
| 2024-08-22 | ScotiaBank | Initiate | Sector Outperform |
| 2023-06-01 | Baird | Initiate | Outperform |
| 2022-05-24 | BTIG | Maintains | Buy |
| 2022-05-24 | B. Riley Securities | Downgrade | Buy -> Neutral |
| 2022-01-24 | B. Riley Securities | Maintains | Buy |
| 2021-04-21 | B. Riley FBR | Initiate | Buy |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- Mar 25, 2026
- Period
- Q4 / 2025
- EPS Estimate
- -$0.27
- Revenue Estimate
- Revenue Q2Q
- N/A
- EPS Q2Q
- 33.70%
- Number of Analysts
- 6
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
-6.85%
EPS (3 Months)
4.41%
Next Earnings Summary
INMB is expected to report earnings on 3/25/2026. The consensus EPS estimate for the next earnings is -0.27 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 370K 105.56% | 155K -58.11% | 14K -90.97% | 51K 264.29% | -100.00% | 6.82M | 31.58M 363.05% | 100.73M 218.97% | 176.67M 75.39% | 265.51M 50.29% | 351.86M 32.52% | 407.11M 15.70% | |
| EBITDA YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -25.95M 10.98% | -29.741M -14.61% | -42.635M -43.35% | -50.332M -18.05% | -31.414M 37.59% | -36.42M -15.93% | -33.486M 8.06% | 36.276M 208.33% | 89.286M 146.13% | 168.15M 88.33% | 239.52M 42.44% | 284.36M 18.72% | |
| Operating Margin | -7,013.51% | -19,187.74% | -304,535.71% | -98,691.00% | N/A | -534.01% | -106.03% | 36.01% | 50.54% | 63.33% | 68.07% | 69.85% | |
| EPS YoY % growth | -1.52 18.28% | -1.67 -9.87% | -2.11 -26.35% | -1.96 7.18% | -0.94 52.21% | -0.99 -6.09% | -0.80 19.86% | 1.03 229.49% | 2.54 146.53% | 4.75 87.15% | 6.74 41.85% | 7.58 12.41% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.27 33.70% | -0.24 43.07% | -0.21 79.60% | -0.26 -8.38% | -0.17 34.62% |
| Revenue Q2Q % growth | -100.00% | 1.988M | |||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -7.271M 23.20% | -6.949M 29.84% | -6.479M 19.59% | -8.919M -19.99% | -5.653M 22.26% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
15.22%
EPS Next 5 Year
20.00%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
760.33%
Revenue Next 5 Year
523.27%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
INMUNE BIO INC / INMB Forecast FAQ
When does INMUNE BIO INC (INMB) report earnings?
INMUNE BIO INC (INMB) will report earnings on 2026-03-25, after the market close.
What are the consensus estimates for INMUNE BIO INC (INMB) next earnings?
The consensus EPS estimate for the next earnings of INMUNE BIO INC (INMB) is -0.27 USD and the consensus revenue estimate is 0 USD.
What is the consensus rating for INMB stock?
The consensus rating for INMUNE BIO INC (INMB) is 80 / 100 . This indicates that analysts generally have a positive outlook on the stock.